Skip to content

Tranexamic Acid for reduction of intra- and postoperative TRansfusion Requirements in elective Abdominal surgery: randomized controlled trial (TATRA)

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2023-509970-43-01
Acronym
KKSH-190
Enrollment
850
Registered
2024-04-25
Start date
2024-06-17
Completion date
Unknown
Last updated
2025-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

and hepatectomy, bleeding and transfusion requirements for major abdominal surgery, colectomy, esophagectomy, gastrectomy, i.e., pancreatic resection, rectal resection

Brief summary

Intra- or postoperative transfusion of at least one unit of Packed Red Blood Cells (PRBCs)

Detailed description

- Number of transfused Packed Red Blood Cells per patient - Estimated amount of intraoperative blood loss - Time to transfusion - Number and severity of postoperative in-hospital complications/mortality (max. 30 days) - Duration of hospital stay - Operation / Anaesthesia duration - D-dimer levels - Quality of life

Interventions

DRUGTranexamsäure Carinopharm 100mg/ml Injektions-/Infusionslösung

Sponsors

Martin-Luther-Universitaet Halle-Wittenberg
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
Intra- or postoperative transfusion of at least one unit of Packed Red Blood Cells (PRBCs)

Secondary

MeasureTime frame
- Number of transfused Packed Red Blood Cells per patient - Estimated amount of intraoperative blood loss - Time to transfusion - Number and severity of postoperative in-hospital complications/mortality (max. 30 days) - Duration of hospital stay - Operation / Anaesthesia duration - D-dimer levels - Quality of life

Countries

Germany

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 6, 2026